Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium

Rhea-AI Summary

Chimerix (NASDAQ: CMRX), a biopharmaceutical company focused on developing life-saving medicines, has announced its participation in the upcoming JonesTrading Virtual Precision Medicine Symposium. Mike Andriole, CEO, and Tom Riga, Chief Operating and Commercial Officer, will engage in a fireside chat on Monday, February 3, 2025, at 11:00 a.m. ET.

The presentation will be accessible via audio webcast through the Investor Relations section of Chimerix's website at ir.chimerix.com. The recording will remain available for approximately 90 days following the event.

News Market Reaction – CMRX

+0.98%

+0.98% Session move

In the trading session that priced this news, CMRX gained 0.98%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in a fireside chat at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025 at 11:00 a.m. ET.

An audio webcast of the panel discussion will be available on the Investor Relations section of Chimerix’s website at ir.chimerix.com, where it will be archived for approximately 90 days.

About Chimerix
Chimerix is a biopharmaceutical company with a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The Company’s most advanced clinical-stage development program, dordaviprone, is in development for H3 K27M-mutant glioma. The Company is conducting Phase 1 dose escalation studies of ONC206 to evaluate safety and PK data.

INVESTOR CONTACT:
Will O’Connor
Stern Investor Relations
will.oconnor@sternir.com

MEDIA CONTACT:
Dana Davis
Steelwire      
dana@steelwire.co

FAQ

When is Chimerix (CMRX) presenting at the JonesTrading Virtual Precision Medicine Symposium?

Chimerix will present at the JonesTrading Virtual Precision Medicine Symposium on Monday, February 3, 2025, at 11:00 a.m. ET.

How can investors access Chimerix's (CMRX) presentation at the JonesTrading Symposium?

Investors can access the audio webcast through the Investor Relations section of Chimerix's website at ir.chimerix.com.

How long will Chimerix's (CMRX) JonesTrading Symposium presentation be available online?

The audio webcast will be archived and available for approximately 90 days on Chimerix's investor relations website.

Which Chimerix (CMRX) executives are participating in the JonesTrading Symposium?

Mike Andriole, Chief Executive Officer, and Tom Riga, Chief Operating and Commercial Officer, will participate in the fireside chat.